Crisantaspase
As of the edition of 20 October 2026, Crisantaspase is an enzyme: marketed, first approved in 2016 (JP).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Enzyme
- Brand name
- Enrylaze
- First approved
- 19 December 2016 (JP)
- Approvals on record
- 5 in 5 regions
- Holder of the most recent approval
- Jazz Pharmaceuticals; 4 holders in all
- Registered trials
- 18, 6 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 10 | 2 | 3 | 5 |
| Phase 3 | 3 | 0 | 3 | 0 |
| All trials | 18 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Jazz Pharmaceuticals | Applicant and Lead sponsor of trials | 2014 to now |